Talon’s Marqibo Gets Lukewarm Endorsement From ODAC
This article was originally published in The Pink Sheet Daily
Executive Summary
A split Oncologic Drugs Advisory Committee vote moves Talon Therapeutics’ Marqibo (vincristine sulfate liposomal injection) for relapsed Philadelphia chromosome negative acute lymphoblastic leukemia one step closer to accelerated approval.